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Background: Tumor debulking surgery followed by adjuvant chemotherapy or radiotherapy is a standard
treatment for many solid malignancies. Although this approach can be effective, it often has limited success
against recurrent or metastatic cancers and new multimodality approaches are needed. Adjuvant immunotherapy is
another potentially effective approach. We therefore tested the efficacy of the TLR7 agonist imiquimod (IMQ)
combined with agonistic anti-CD40 in an incomplete debulking model of malignant mesothelioma.
Methods: Established subcutaneous murine ABA-HA mesothelioma tumors in BALB/c mice were surgically
debulked by 75% and treated with either: i) saline; ii) intratumoral IMQ; iii) systemic anti-CD40 antibody, or using a
combination of IMQ and anti-CD40. Tumour growth and survival were monitored, and the role of anti-tumor CD4
and CD8 T cells in therapeutic responses was determined.
Results: The combination therapy of partial debulking surgery, IMQ and anti-CD40 significantly delayed tumor
growth in a CD8 T cell dependent manner, and promoted tumor regression in 25% of animals with establishment
of immunological memory. This response was associated with an increase in ICOS+ CD8 T cells and tumor-specific
CTL activity in tumor draining lymph nodes along with an increase in ICOS+ CD8 T cells in responding tumours.
Conclusions: We show that the post-surgical environment can be significantly altered by the co-administration of
adjuvant IMQ and anti-CD40, resulting in strong, systemic anti-tumor activity. Both adjuvants are available for clinical
use/trial, hence this treatment regimen has clear translational potential.
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Surgical removal of solid tumors aims to provide long
term, cancer-free survival. Macroscopic tumour eradica-
tion is achieved successfully in many cases, however, re-
lapses can and do occur in some patients. This is mainly
due to the inability to completely access and resect the
primary tumor, or to the existence of micrometastases at
the time of surgery. On-going attempts to improve this* Correspondence: bruce.robinson@uwa.edu.au
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unless otherwise stated.situation by the use of adjuvant chemotherapy and/or
radiotherapy have met with some success, with significant
results seen in breast and colorectal cancer, for example
[1,2]. However, in many other cancer types, treatments de-
livered post surgery have only limited effect and thus new
adjuvant approaches are needed [3].
Adjuvant immunotherapy is gaining renewed interest
due to the recent success of checkpoint blockade with
drugs such as anti-CTLA-4 and anti-PD-1 [4]. Here we
examine the benefits, and mode of action, of a com-
bined adjuvant immunotherapy of imiquimod (IMQ)
and systemic agonistic anti-CD40 antibody to treat in-
completely debulked AB1-HA tumors. IMQ is a potent
toll-like receptor-7 (TLR7) stimulator with anti-tumorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and activation to aid cross-priming of CD8 T cell responses
to tumor antigens. To date, IMQ is one of only three TLR
agonists that are FDA-approved for use in human cancer
[5]. Agonistic anti-CD40 (CP-870,893) further promotes
DC-driven cytotoxic T lymphocyte (CTL) responses
through its ability to substitute for CD4 T help [6] and has
shown some success in clinical trials due to its synergism
with chemotherapy [7,8]. It is also noted for its ability to
drive effector cells from the lymph nodes (LN) to the per-
iphery [9], and in combination with IMQ has demonstrated
efficacy against mesothelioma in our mouse model [10].
The AB1-HA mesothelioma tumor is one of the few mur-
ine tumor models that closely resembles the homologous
human disease, in terms of its defined aetiology, biology
and clinical behaviour, meaning that the results described
in this study are applicable to human tumors [11].
Methods
Mice
BALB/c (H-2d) (Specific Pathogen Free (SPF), female,
6–8 weeks of age) mice were obtained from the Animal
Resources Centre (Western Australia) and maintained
under standard conditions at the University of Western
Australia (UWA) QEII Medical Centre animal holding
facility. All experiments were performed with approval
from the UWA Animal Ethics Committee.Tumor cells and inoculation
The AB1-HA murine malignant mesothelioma cell line was
generated in our lab as described previously [11]. Cells were
maintained in RPMI 1640 (Life Technologies, Australia)
supplemented with 20 mM HEPES (Sigma-Aldrich,
Australia), 0.05 mM 2-ME, 60 μg/ml penicillin (CSL,
Australia), 50 μg/ml gentamicin (Pfizer, Australia), 10%
foetal calf serum (FCS; Life Technologies, Australia), and
400 μg/ml Geneticin (G418; Life Technologies, Australia).
Trypsinised adherent cells were counted and viability
assessed by trypan blue exclusion. Cells were resuspended
in phosphate buffered saline (PBS) at 5 × 106 cells/ml and
100 μl injected subcutaneously (s.c) into the shaved, right
hand flank of mice. In some mice, tumors were inoculated
7 days later to act as size-matched controls i.e., non-
debulked tumor size matches debulked tumor size at com-
mencement of treatment. Tumor size was monitored by
electronic callipers and calculated by multiplying the
length and width to produce tumor area in mm2. Mice
were euthanised when tumors reached 100 mm2 accord-
ing to UWA Animal Ethics guidelines.Surgical debulking
Primary tumors were partially debulked on day 18 post-
inoculation when tumors were approximately 50 mm2 insize. Mice were anaesthetised by induction under inhal-
ant methoxyflurane (1 ml/20 g) and maintenance under
isoflurane with 5% oxygen. The surgical area was sprayed
with 70% ethanol and approximately 75% of the tumor
was removed, leaving 25% in situ. The area was closed
using staples (LT-100 liga clips, Ethicon, North Ryde,
Australia) or 5/0 vicryl continuous sutures (Ethicon). Mice
were placed under a heat lamp for recovery and received
0.5 mg/kg buprenorphine immediately post surgery.
Treatments
IMQ [Aldara™ (3 M Pharmaceuticals)] was administered
by intratumoral (i.t.) injection at 50 μg once daily for
6 days starting at the time of surgery. Anti-CD40 (FGK45;
Ab Solutions, Perth, Australia) treatment commenced
on day 19 at 100 μg administered intraperitoneally
(i.p.) given every second day for three doses. For cell
depletion studies, anti-CD4 (GK1.5) or anti-CD8 (YTS.169)
(Ab Solutions, Perth, Australia) was administered from
day 17 (1 day pre-surgery), given every second day for
a total of three doses. The initial dose was given intraven-
ously (i.v.), followed by two i.p. injections of 150 μg.
In vivo CTL assay by flow cytometry
In vivo tumor-specific CTL activity was measured as
previously described [12]. Briefly, spleens and lymph
nodes were isolated from BALB/c mice and disaggre-
gated between frosted glass sides, erythrocytes were
lysed using PharmLyse (BD) and the remaining lympho-
cytes were washed well with PBS. Lymphocytes were
then divided into two populations, and either pulsed
with CL4 peptide (1 μg/ml for 90 mins at 37°C) and la-
belled with a high dose of carboxyfluorescein succinimi-
dyl ester (CFSE) (5 μM) or un-pulsed and labelled with a
low dose of CFSE (0.5 μM). Both cell populations were
combined at a 1:1 ratio and adoptively transferred i.v.
into recipient tumor-bearing animals. Twenty hours
after transfer, lymphocytes were recovered from lymph
nodes and spleens, as described above, analysed by FACS
for fluorescence intensity staining in the FITC channel.
The percentage of tumor-specific CTL was calculated by
dividing the percentage of un-pulsed cells (CFSE lo) by
the percentage of CL4-pulsed target cells (CFSE hi).
Flow cytometric assessment of T cell activation
For flow cytometric analysis, spleens, lymph nodes and tu-
mors were harvested and processed into single cell sus-
pensions. The axillary and inguinal lymph nodes were
pooled for the tumor flank (draining LNs) and healthy
contralateral flank (non-draining LNs). Tissues were
disaggregated by rubbing between frosted glass slides.
Erythrocytes were lysed using Pharmlyse (BD Biosciences,
Australia). Cells were filtered by passing through a
70 μm mesh, then surface-stained using the following
Khong et al. BMC Cancer 2014, 14:969 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/969antibodies; CD4 PE-Cy7 (eBioscience; Cat. 25-0042-82),
CD8 PE-Cy5.5 (abcam; Cat. 37928) and ICOS APC (Biole-
gend; Cat. 313510). Data were acquired on a FACSCantoII
(BD Biosciences, Australia) by collecting 100,000 events in
the lymphocyte gate, and analysed using FlowJo software
(Treestar, USA) for the percentage of CD4+ and CD8+ T
cell subsets within the lymphocyte gate, and the percent-
age of each subset expressing ICOS.
Statistical analysis
Each experiment contained a minimum of 5 mice per
group and was repeated at least twice. Statistical analysis
was performed using GraphPad Prism software (San
Diego, CA, USA). Tumour growth curves were analysed
using the Mann–Whitney non-parametric test and the
log rank test was used for Kaplan Meier survival plots
(Figures 1, 2, 3 & 4). The Kruskall-Wallis test with Dunn’s
correction for multiple comparisons was used to compare
differences in% CTL or% lymphocytes between treatment
groups (Figures 5, 6 & 7). Differences were considered sig-
nificant if the p value was less than 0.05.
Results
Partial debulking of 75% of the tumor mass provides the
best scenario for adding adjuvant immunotherapy
We first established our model of partial tumor debulking
by investigating the effects of removing different propor-
tions of tumor mass on the growth of residual tumor and
overall survival (Figure 1). Complete resection of the
tumor was attempted and achieved in 4 out of 6 mice and
resulted in tumor-free survival >100 days (Figure 1A).
Tumor outgrowth in the remaining 2 mice for which
complete debulking was ineffective was delayed for
~15 days before rapid growth of residual tumour cells over
a further 15 days (Figure 1B). When 75% of the tumor was
debulked, <20% of animals had tumor-free survival
(Figure 1A) but tumor outgrowth in the remaining ani-
mals was relatively slow, with the last mouse culled 32 days
post surgery (Figure 1B). In contrast, when 50% or less ofFigure 1 75% debulk results in delayed residual tumor outgrowth. BA
different percentages on day 18 post-tumour inoculation (dotted line). A. S
mice shown in brackets. ***p < 0.001 compared to untreated; log-rank test.the tumor was debulked, tumor growth rates and tumor-
free survival benefit were indistinguishable from sham-
treated animals (Figure 1A & B). There were no changes
in the proportion of activated (ICOS+) CD4 or CD8 T
cells in the different surgical debulking groups either in
the tumor itself or in the peripheral lymphoid organs
(data not shown). We used a modified dye dilution
assay to test the functional efficacy of CTL in vivo [13].
In all cases, effector CTL responses were below the limits
of detection (data not shown) suggesting that surgical
debulking alone does not lead to systemic immune activa-
tion even in the context of slower tumor growth rate.
Debulking of 75% of tumor mass was chosen for subse-
quent experiments to determine if a window of opportun-
ity for adjuvant immune therapy exists after incomplete
tumor resection.
Local IMQ therapy boosts the survival benefit of tumor
debulking surgery in a CD8 dependent manner
To investigate the efficacy of IMQ in the post-surgical
environment, we compared the outgrowth of residual,
debulked tumors to size-matched, unresected control tu-
mors (inoculated 7 days later than debulked mice) fol-
lowing administration of IMQ. Intratumoral injections
can potentially cause immune and inflammatory stimu-
lation, however we have shown in previous studies that
i.t. administration of saline does not affect subcutaneous
tumor outgrowth, nor cause the release of type I IFNs or
promote antigen-specific immune responses [10]. Con-
trol i.t. injections were therefore not included in the
present study. There was no significant difference be-
tween the treatment groups in terms of the rate of
tumor outgrowth, however, debulk plus adjuvant IMQ
produced a growth delay of up to 30 days with 20% sur-
vival in excess of 50 days (Figure 2). These surviving
mice were also shown to have developed tumor-specific
memory, as demonstrated by resistance to rechallenge
with parental AB1 tumor cells inoculated into the
contralateral flank.LB/c mice bearing AB1-HA tumors underwent surgical debulking of
urvival and B. Residual tumour outgrowth were monitored. Surviving
Figure 2 CD8 T cells are absolutely required for the survival benefit of combined surgery and IMQ treatment. BALB/c mice bearing
AB1-HA tumors were left untreated or partially (75%) surgically debulked (dotted line) of tumor, then treated with immunotherapy (IMQ; 50 μg i.t.
q1dx6 on day of surgery; shaded box) and anti-CD4 (GK1.5) or anti-CD8 (YTS.169) specific antibodies (arrows) administered from day 17 (1 day
pre-surgery), given every second day for a total of three doses. The initial dose was given intravenously (i.v.), followed by two i.p. injections of
150 μg. A) Survival curves of treatment groups as indicated. Number of survivors/total number of animals in parentheses. ***p =0.0004 comparing
75% debulk + IMQ + anti-CD8 to 75% debulk + IMQ, **p = 0.0014 comparing debulk alone to debulk + IMQ; log-rank test B) Tumor growth curves
of treatment groups as indicated (survivors with complete tumour regression not included).
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ment for CD8 T cells in the anti-tumor response elicited
by adjuvant IMQ therapy. In contrast to CD4 T cell deple-
tion, which did not result in any long-term survivors, de-
pletion of CD8 T cells resulted in a significantly decreased
survival and increased residual tumour outgrowth com-
pared to debulk plus IMQ ([14] and Figure 2).
Agonistic anti-CD40 therapy boosts the survival benefit of
combined tumor debulking surgery and local IMQ therapy
A lack of CD4 T cell infiltrate has previously been re-
ported for locally administered IMQ, and can be im-
proved by co-administration of agonistic anti-CD40
antibody [10]. Thus our next step was to determine
whether the addition of anti-CD40, administered on the
day of surgery, could further improve the outcomeFigure 3 Anti-CD40 therapy boosts the survival benefit of combined
bearing AB1-HA tumors were left untreated or partially (75%) surgically debulk
i.t., q1dx6; shaded box) and α-CD40 antibody (FGK45; 100 μg i.p. q2dx3, startin
treatment groups as indicated. Number of survivors/total number of animals i
IMQ+ α-CD40) to debulk only; log-rank test B. Tumor growth curves of treatmrelative to debulking surgery and adjuvant IMQ.
Addition of anti-CD40 to debulking surgery led to a sur-
vival delay of approximately 7 days more than untreated
mice. This was comparable to debulk alone, which con-
ferred a survival delay of approximately 5 days more
than untreated mice (Figure 3A). Residual tumor out-
growth following debulk plus anti-CD40 was delayed by
2–3 days compared to debulk alone (Figure 3B). In con-
trast, the combination of debulk plus IMQ plus anti-
CD40 produced a significant survival advantage of
10 days over debulk alone (p < 0.0001; Figure 3A), and
residual outgrowth was markedly slower than either
debulk plus IMQ, or debulk plus anti-CD40
(Figure 3B). Thus, the combination of anti-CD40 ther-
apy and IMQ provided a significant advantage to
debulking surgery compared to surgery alone, and wastumor debulking surgery and local IMQ therapy. BALB/c mice
ed (dotted line) of tumor, then treated with immunotherapy (IMQ; 50 μg
g one day after surgery and IMQ treatment; arrows). A. Survival curves of
n brackets. ****, p < 0.0001, comparing (debulk + IMQ) and (debulk +
ent groups as indicated.
Figure 4 Anti-CD40 enhances local but not systemic CTL
responses induced by IMQ. BALB/c mice bearing AB1-HA tumors
were left untreated or partially (75%) surgically debulked of tumor
then treated with immunotherapy (IMQ; 50 μg i.t. q1dx6 on day of
surgery and/or anti-CD40; 100 μg i.p. q1dx1, starting one day after
surgery). CFSE-labelled, CL4-pulsed and un-pulsed target cells were
injected i.v. on day 25 post inoculation and 18 hours later the dLN,
ndLN and spleen were harvested and analysed by flow cytometry to
assess levels of CTL activity. ns = not significant, *p < 0.05, **p < 0.01
compared to untreated; Kruskal-Wallis test with Dunn’s correction for
multiple comparisons.
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ther IMQ or anti-CD40.
Anti-CD40 enhances CTL responses induced by IMQ
following debulking surgery
We next investigated the effect of adding anti-CD40 to
the CTL responses and activation status of specific T cell
subsets. The addition of IMQ to debulking surgery led
to increased CTL in the dLN, ndLN and spleen, com-
pared to debulk alone (Figure 4). Similarly, addition ofFigure 5 T cell proportions and activation in the spleen following com
mice bearing AB1-HA tumors underwent debulking surgery and treatment
(100 μg i.p. q1dx1, starting one day after surgery). On day 26, the spleens w
and CD8+ T cells were identified as% of total lymphocytes (based on forw
status) as% of total CD4+ or CD8+ T cells. *p < 0.05, **p < 0.01, ***p < 0.001
multiple comparisons.anti-CD40 to debulking surgery led to increases in CTL
in the dLN, ndLN and spleen (19%, 6% and 4% respect-
ively) compared to debulking alone (3%, 3% and
1%, respectively) (Figure 4). Combination treatment of
debulking surgery with IMQ and anti-CD40 resulted in
significant increases in CTL killing to over 45% in the
dLN (p < 0.001), 15% in the ndLN (p < 0.05) and 15% in
the spleen (p < 0.01) (Figure 4). These results demon-
strate that the triple therapy produces CTL responses
that are greater than debulk alone, or debulk with either
IMQ or anti-CD40 therapy.
We also analysed T cell subset distribution and activation
status in the dLN, spleen and tumour following each of the
different treatment combinations. Overall, there was no sig-
nificant difference between CD4 and CD8 T cell propor-
tions and activation following debulking surgery compared
to untreated mice, in all tissues analysed (Figure 6). In the
dLN, we found that mice receiving debulk + IMQ exhibited
a slight increase in the percentage of both CD4 and CD8 T
cells compared to debulk alone, while the activation status
(ICOS expression) of CD4 T and CD8 T cells remained un-
changed compared to both debulk alone and untreated
mice (Figure 6). In contrast, anti-CD40 treatment (either
with debulk alone, or debulk + IMQ) resulted in significantly
decreased percentages of CD4 and CD8 T cells in the dLN
(p < 0.001), while activation status of both subsets was sig-
nificantly increased, particularly CD8 T cells (p < 0.001)
compared to debulking alone (Figure 6). Similar trends were
observed in the spleen, with addition of anti-CD40 treat-
ment leading to significantly decreased percentages of CD4
and CD8 T cells and increased ICOS expression in both
subsets compared to debulk only (Figure 5).
In the tumor, we observed an overall trend towards
lower percentages of CD4 T cells and higher activation
status in all treatment groups compared to untreated,bined debulking surgery with IMQ and/or anti-CD40. BALB/c
with IMQ (50 μg i.t. q1dx6 on day of surgery) and/or anti-CD40
ere removed for analysis of T cell subsets by flow cytometry. CD4+
ard and side scatter), and analysed for ICOS expression (activation
compared to untreated; Kruskal-Wallis test with Dunn’s correction for
Figure 6 T cell proportions and activation in the draining lymph nodes following combined debulking surgery with IMQ and/or
anti-CD40. BALB/c mice bearing AB1-HA tumors underwent debulking surgery and treatment with IMQ (50 μg i.t. q1dx6 on day of surgery)
and/or anti-CD40 (100 μg i.p. q1dx1, starting one day after surgery). On day 26, the draining lymph nodes were removed for analysis of T cell
subsets by flow cytometry. CD4+ and CD8+ T cells were identified as% of total lymphocytes (based on forward and side scatter), and analysed
for ICOS expression (activation status) as% of total CD4+ or CD8+ T cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated; Kruskal-Wallis
test with Dunn’s correction for multiple comparisons.
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debulk + IMQ + anti-CD40 group (CD4 T cells, p < 0.05;
Figure 7). CD8 T cell proportions in all treated groups
were similar to untreated, apart from a 3% increase in
the debulk + IMQ treated group. There was also a trend
towards increasing CD8 T cell activation, with >10% in-
crease following debulk + anti-CD40 and >20% increase
following debulk + IMQ + anti-CD40 (Figure 7).
Taken together, these data indicate that following anti-
CD40 administration the proportion of T cells did not ex-
pand but were significantly more activated. An important
observation was that the dLN and spleens of all mice
treated with anti-CD40 were more than doubled in size
compared to other treatment groups (not shown). This
may account for the lower percentage of immune cells, asFigure 7 T cell proportions and activation in the tumor following com
bearing AB1-HA tumors underwent debulking surgery and treatment with IM
q1dx1, starting one day after surgery). On day 26, the tumors were removed f
were identified as% of total lymphocytes (based on forward and side scatter),
CD8+ T cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated; Kruskaa proportion of total splenocytes, found in these mice.
Thus anti-CD40 enhances the effect of debulk alone
through its ability to activate T cell subsets, and is able to
boost the additional action of IMQ by increasing CTL in
the dLN.
Discussion
Occult residual tumor at the resection site or metastatic
deposits can often limit the success of surgery as a can-
cer treatment. Immunotherapy represents a potentially
useful adjuvant after cancer surgery to eliminate any
remaining tumor cells by inducing antigen-specific anti-
tumor activity and stimulating the patient’s immune re-
sponse to attack residual tumour cells. In this study we
investigated agents that target the dendritic cell (DC)bined debulking surgery with IMQ and/or anti-CD40. BALB/c mice
Q (50 μg i.t. q1dx6 on day of surgery) and/or anti-CD40 (100 μg i.p.
or analysis of T cell subsets by flow cytometry. CD4+ and CD8+ T cells
and analysed for ICOS expression (activation status) as% of total CD4+ or
l-Wallis test with Dunn’s correction for multiple comparisons.
Figure 8 Immune accelerators acting on remaining tumor after debulking surgery induce a systemic anti-tumor response capable of
attacking local residual tumor. In cases of incomplete debulking surgery, local delivery of IMQ into the tumor site combined with systemic
delivery of activating anti-CD40 is an effective approach to promote DC activation and cross-priming of CD8 T cells, leading to a systemic
anti-tumor response capable of attacking residual primary tumor deposits and, potentially, secondary metastatic deposits.
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and orchestrating anti-tumor responses. The combined
regimen of TLR7 stimulation (IMQ) and activating im-
munotherapy (anti-CD40) represent two powerful means
of activating DCs [10].
Benefits of administering immunotherapy after surgical
debulking
We hypothesised that in cases where complete tumor re-
section is not possible, there is an optimal amount of
tumour to debulk that provides the best environment for
adjuvant therapy. As indicated in our model, this is ap-
proximately 75% of medium-sized, established tumours.
This result is encouraging as it suggests that even with
larger-sized, difficult to access, or more advanced tumours
where surgery may not be considered the best course of
treatment i.e., mesothelioma, if the majority of it can be
removed then this will provide a good opportunity for ad-
juvant immunotherapy to work.
Surgery provides an opportunity for local therapy
There are several theoretical advantages of providing
immunotherapy in a post-surgical setting; the post-
surgical environment is altered due to the presence of
wound-healing inflammatory mediators, while cytore-
duction removes tumor suppressive elements [15] and
leads to smaller tumors which are generally more sus-
ceptible to immunotherapy [16,17]. Surgery provides
access to the tumor site and thus presents an opportun-
ity for drugs to be administered directly into the tumor,
an approach often not possible due to the deep location
of many tumors within the body. On a physiologicallevel, localised drug delivery may result in increased
potency at the required site of action while at the same
time reducing systemic toxicity [18]. The other positive
aspects of localised intratumoral drug delivery include
the potential conversion of the tumor into its own vac-
cine [19-21] as well as the potential to produce a sys-
temic effect.
In our model of mouse mesothelioma we have previ-
ously tested a variety of dosing regimens and routes and
identified that the optimal method of administration of
IMQ was to deliver it directly into the tumor on consecu-
tive days [10,14]. In the current study we found that there
was a clear survival advantage with the co-administration
of intra-tumorally injected IMQ following debulking sur-
gery, in part due to increased CTL and CD8 T cell activa-
tion and the generation of immunological memory.
Importantly, given the that surgery can also be potentially
immunosuppressive, we note that in fact the act of surgery
itself did not adversely affect the efficacy of adjuvant IMQ.
This suggests that IMQ and potentially other immune-
potentiating agents are suitable drugs for administration
post surgery.
Addition of anti-CD40 improves the anti-tumor response
via release of effector T cells
The concept of combining immunisation with co-
stimulation has been explored in several murine cancer
models. We have previously shown that agonistic anti-
CD40 is effective in a number of post-operative set-
tings [22,23], and that IMQ and anti-CD40 may be
combined effectively to treat tumors [10,22,24,25].
In this study, IMQ and anti-CD40 were chosen
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CD8 T cell egress from the draining lymph nodes [9]
and their likely role in improving CD8 entry/function
at the effector site [26]. We found that CTL responses
were significantly enhanced in the periphery (ndLN
and spleen), and more so in the local dLN following
surgery with IMQ and anti-CD40 (Figure 3). This is in
con- trast with what has been
found by others, e.g., co-administration of IMQ and
anti-CD40 is ineffective against intradermal B16 mela-
nomas, and required a combination of TLR3, TLR4
and TLR7 stimulation to produce 50% tumor rejection
[25]. This highlights the effectiveness of this combin-
ation in our model, but in general suggests a multi-
targeted approach may be ideal. Indeed, a preclinical
surgical study using the renal cell carcinoma model has
shown that anti-CD40 may be successfully combined
with IL-2 to orchestrate effective DC and CD8 T cell
response against distal tumours [27]. It may also indi-
cate a need to overcome residual tumor immune sup-
pression. A recent preclinical study showed that low dose
anti-CTLA-4 delivered i.t. caused a reduction in tumor-
associated Tregs and regression of a distal tumor [18]. For
future studies it would be interesting to incorporate a
combination of immunotherapies that ‘accelerate’ the im-
mune response (i.e., anti-CD40) and release the ‘brakes’
on existing responses (i.e., anti-CTLA-4, anti-PD-1) to
produce an even stronger immune response after surgery
[28,29].Conclusion
We have shown that debulking surgery alone alters the
dynamics of the immune response by changing the pro-
portions of CD4 and CD8 T cells. In the context of this
new post-surgical environment, cells of the immune
system can be further activated by the synergistic com-
bination of TLR7 stimulation and anti-CD40, resulting
in improved outcomes. A summary of how these agents
are believed to work together is shown in Figure 8. Im-
portantly, these data indicate the unique post-surgical
environment should be considered an opportunity to
administer immune-modulating agents to target inoper-
able, residual or metastatic tumor, an approach warrant-
ing future clinical study. Further investigations are
needed to identify which therapies are beneficial for
which cancers, and what are the mechanisms or cell
types are involved in the response. Nevertheless, this
study indicates the potential for adjuvant therapies to
change the course or nature of surgical management for
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